EX-15.1 9 ea023342201ex15-1_ascentage.htm CONSENT OF ERNST & YOUNG HUA MING LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statement (Form S-8 No.333-284445) pertaining to the Pre-IPO Share Option Plan, Post-IPO Share Option Plan, 2018 Restricted Share Unit Scheme, 2021 Restricted Share Unit Scheme and 2022 Restricted Share Unit Scheme of Ascentage Pharma Group International of our report dated April 16, 2025, with respect to the consolidated financial statements of Ascentage Pharma Group International included in this Annual Report (Form 20-F) for the year ended December 31, 2024.

/s/ Ernst & Young Hua Ming LLP

Shanghai, the People’s Republic of China

April 16, 2025